Sebaceous carcinoma: evidence-based clinical practice guidelines

Owen, Joshua L.; Kibbi, Nour; Worley, Brandon; Kelm, Ryan C.; Wang, Jordan V; Barker, Christopher A.; Behshad, Ramona; Bichakjian, Christopher K.; Bolotin, Diana; Bordeaux, Jeremy S.; Bradshaw, Scott H.; Cartee, Todd V.; Chandra, Sunandana; Cho, Nancy L.; Choi, Jennifer N.; Council, M. Laurin; Demirci, Hakan; Eisen, Daniel B.; Esmaeli, Bita; Golda, Nicholas; Huang, Conway C.; Ibrahim, Sherrif F.; Jiang, S. Brian; Kim, John; Kuzel, Timothy M.; Lai, Stephen Y.; Lawrence, Naomi; Lee, Erica H.; Leitenberger, Justin J.; Maher, Ian A.; Mann, Margaret; Minkis, Kira; Mittal, Bharat B.; Nehal, Kishwer S.; Neuhaus, Isaac M.; Ozog, David M.; Petersen, Brian; Rotemberg, Veronica; Samant, Sandeep; Samie, Faramarz H.; Servaes, Sabah; Shields, Carol L.; Shin, Thuzar M.; Sobanko, Joseph F.; Somani, Ally‐Khan; Stebbins, William G.; Thomas, J. Regan; Thomas, Valencia D.; Tse, David T.; Waldman, Abigail; Wong, Michael K.; Xu, Yaohui; Yu, Siegrid S.; Zeitouni, Nathalie C.; Ramsay, Timothy; Reynolds, Kelly A.; Poon, Emily; Alam, Murad

doi:10.1016/s1470-2045(19)30673-4

Cited by 128 publications

(254 citation statements)

References 85 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…The longest diagnostic delay was related to misdiagnosis as chalazion, especially in patients with recurrent surgical treatment before reaching the correct diagnosis of SC. This emphasizes the importance of biopsy when tumours diagnosed as benign at onset do not heal as expected (Owen et al 2019). On the other hand, one should remember that chalazion is a common eye disease in our catchment area; approximately 350 patients with chalazion were treated annually in our hospital during the study period, and approximately 50 of them were older than 65 years.…”

Section: Discussionmentioning

confidence: 54%

“…A study from the United States recommends map biopsies in all patients with SC (McConnell et al 2017). But a recent review article recommended to consider map biopsies, if intraepithelial growth was found in primary biopsy (Owen et al 2019).…”

Section: Discussionmentioning

confidence: 99%

“…Until recently, no treatment guidelines for SC were available in Finland or globally (Leivo et al 2020). Such guidelines including additional treatments have been recently written and will hopefully lead to better treatment standards (Esmaeli et al AJCC Cancer Staging Manual, 8th Ed 2017; Owen et al 2019).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Sebaceous carcinoma of the eyelid: 21‐year experience in a Nordic country

Niinimäki

Siuko

Tynninen

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To evaluate the clinical features, diagnostic challenges, management, and prognosis of sebaceous carcinoma (SC) of the eyelids and periocular region in a Nordic country. Methods Patients were identified from the Finnish Cancer Registry and the Helsinki University Hospital databases during the 21‐year period 1998–2018. Age, sex, location, clinical and histopathologic diagnosis, treatment and outcome were registered. Results Sebaceous carcinoma (SC) was diagnosed in 32 patients. The incidence was 0.6 per million. Median age at the time of histopathologic diagnosis was 74 years, and 72% of patients were women. Diagnostic delay was often long, median 12 months. The most common cause for delay was misdiagnosis (72%): a chalazion in 34% and a benign tumour in 22%. The most common location was the upper eyelid (53%) and tumour type a solitary nodule (94%). The SC was not correctly diagnosed in 12 (40%) of 30 preoperative biopsies. The treatment for 31 (97%) patients was complete surgical removal with reconstruction. Conjunctival intraepithelial growth was found in 50%. The leading postoperative problem was ocular irritation (30%). During a median follow‐up of 58 months, two patients (6%) experienced a local recurrence and one patient died from metastatic SC. Conclusions The estimated incidence of SC in Finland was somewhat higher than in other Western countries. The diagnosis was often markedly delayed. Especially differentiation from chalazion continues to be essential. To improve outcomes, it is essential to inform the pathologist about the possibility of SC in eyelid biopsies and specimens and ideally submit them to an ophthalmic pathology service.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sebaceous carcinoma of the eyelid: 21‐year experience in a Nordic country

Niinimäki

Siuko

Tynninen

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Most SGC tumors are located in the extraocular head and neck skin (face/ear/scalp/neck/lip, 42.8%), followed by the eyelid (34.5%), trunk (14.8%), and extremities (6.5%). Ocular SGC arises from the sebaceous glands, whereas the origin of extraocular sebaceous carcinoma has not been determined [ 2 ]. SGC of the eyelid is a malignant eyelid tumor that is derived from sebaceous glands, such as the meibomian gland and Zeis gland.…”

Section: Discussionmentioning

confidence: 99%

A case of repeat resection for recurrent pulmonary metastasis from sebaceous gland carcinoma

et al. 2020

View full text Add to dashboard Cite

Background Sebaceous gland carcinoma (SGC) of the eyelid is an aggressive malignant eyelid tumor, and it can metastasize to the regional lymph nodes and distant organs. There have been only a few reported cases of patients who underwent pulmonary metastasectomy for metastatic SGC. We herein report a patient who underwent repeat pulmonary metastasectomies for recurrent pulmonary metastases from SGC. Case presentation Bilateral small pulmonary nodules were detected in a 59-year-old woman with a history of eyelid SGC. She underwent wide wedge resection of the left lower lobe, and the disease was diagnosed as pulmonary metastases from SGC. Six months after the first pulmonary resection, CT showed that the nodules of right S2 and S10 had increased in size, and three small nodules had newly appeared in the right lung. The patient therefore underwent six wide wedge resections of the right lung through thoracotomy. After that, she underwent pulmonary metastasectomy 2 times. Ninety months after the first pulmonary resection, the patient is doing well without disease. Conclusions Given that a long-term survival was ultimately achieved in the present case, repeat pulmonary metastasectomy may be beneficial for recurrent pulmonary metastasis from SGC.

show abstract

“…CircRNAs usually sponge miRNA to modulate enrgy metabolism, angiogenesis, invasion and metastasis in carcinoma. Recent researches had found that in thyroid cancer, circRNA_10217, circRNA_NEK6 and circ_0067934 could promote tumor growth [19][20][21], while circ-ITCH could suppress tumor progression [22].In this manuscript, we rst screened thyroid cancer related circRNA chips results from GEO database. Then hsa-circ-0012417 was upregulated in thyroid tumor via pPCR in 14 pairs of thyroid tumor tissues and para-carcinoma tissue (Fig.…”

Section: Discussionmentioning

confidence: 99%

Circ-0012417/ miR-29c-5p Axis Stimulates Thyroid Cancer Growth

Zhang¹,

Luo²,

Shi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: There is an increasing tendency of the incidence rate of thyroid cancer. Despite the advance of widespread early diagnose and good prognosis of papillary thyroid cancer (PTC), some patients still suffered from the invasiveness and metastasis of thyroid cancer. More and more evidences demonstrated that circular RNAs (circRNAs) play important roles in tumorigenesis, tumor progression and metastasis. This study aims to identify oncogenic cirRNAs and explore its underlying molecular mechanisms in thyroid cancers.Methods: With circRNA chips in GEO database, we found that circ-0012417 was over-expressed in thyroid cancer. After silencing circ-0012417 or ectopic over-expressed circ-0012417, CCK-8 was used for detecting cell proliferation and transwell is used for examining metastasis and invasion abilities. Western Blot was used to detect changes of downstream proteins. Dual luciferase reporter assay was used to verify whether miR-29c-5p is the target of circ-0012417. Tumor xenografts in nude mice were used for further in vivo verifications. Results: Circ-0012417 is overexpressed in thyroid cancer, and silencing circ-0012417 could inhibit cancer cell proliferation, metastasis and invasion. MiR-29c-5p may be the target of circ-0012417 and inhibiting miR-29c-5p could reverse this phenomenon. And further analysis of TCGA and GTEx databases showed that EGFL7 may be the target of miR-126 and a promising thyroid cancer prognosis indicator.Conclusion: Circ-0012417 promotes thyroid cancer progression through regulating miR-29c-5p /EGFL7 pathway. Our finding provided novel therapeutic targets for thyroid cancer treatment.

show abstract

Sebaceous carcinoma: evidence-based clinical practice guidelines

Cited by 128 publications

References 85 publications

Sebaceous carcinoma of the eyelid: 21‐year experience in a Nordic country

Sebaceous carcinoma of the eyelid: 21‐year experience in a Nordic country

A case of repeat resection for recurrent pulmonary metastasis from sebaceous gland carcinoma

Circ-0012417/ miR-29c-5p Axis Stimulates Thyroid Cancer Growth

Contact Info

Product

Resources

About